Mechanisms of Reduced Susceptibility to Cefiderocol Among Isolates from the CREDIBLE-CR and APEKS-NP Clinical Trials

Patrice Nordmann, Ryan K Shields, Yohei Doi, Miki Takemura, Roger Echols, Yuko Matsunaga, Yoshinori Yamano, Patrice Nordmann, Ryan K Shields, Yohei Doi, Miki Takemura, Roger Echols, Yuko Matsunaga, Yoshinori Yamano

Abstract

The objective of this study was to characterize isolates with reduced susceptibility to cefiderocol in patients receiving cefiderocol for nosocomial pneumonia or carbapenem-resistant infections in the Phase 3 APEKS-NP and CREDIBLE-CR studies. Susceptibility testing of isolates was conducted at a central laboratory, and post-treatment changes were evaluated according to available breakpoints for cefiderocol. Whole-genome sequencing and multilocus sequence typing were performed for isolates to confirm their origin and identify mutations. Five (APEKS-NP) and nine (CREDIBLE-CR) isolates demonstrated a ≥ 4-fold minimum inhibitory concentration (MIC) increase compared with genetically related baseline isolates; most remained susceptible to cefiderocol despite the ≥4-fold MIC increase. Mutations in β-lactamases or penicillin-binding protein (PBP) were identified in 4/14 isolates: one Enterobacter cloacae (amino acid [AA] substitution [A313P] in ACT-17); two Acinetobacter baumannii (one PBP3 AA substitution [H370Y], one with OXA-23 substitutions [N85I and P225S]); and one Pseudomonas aeruginosa (PDC-30 [4AA deletion "TPMA" position 316-319]). Cloning experiments using isogenic Escherichia coli strains containing wild-type and those mutant cephalosporinase enzymes show that the mutant enzymes may contribute to decreased susceptibility to cefiderocol. Pharmacokinetic data were available for nine patients, for whom cefiderocol exposures exceeded 100% fT > 4 × MIC. No clear pattern between mutations and development or extent of MIC increases was observed. No mutations were identified in genes related to iron transport, including fiu, cirA, piuA/C, and pirA, among recovered Gram-negative isolates. Clinicaltrials.gov: APEKS-NP: NCT03032380; CREDIBLE-CR: NCT02714595.

Keywords: MIC increase; cefiderocol; mutation; resistance; susceptibility; whole-genome sequencing.

Conflict of interest statement

P.N. has no conflict of interest relevant for this study. R.K.S. has served as a consultant for Shionogi, Menarini, Melinta, Merck, Entasis, Utility, Venatorx, and Allergan. Y.D. has served as a consultant for Shionogi, Gilead, Janssen, and bioMérieux. Y.M. is an employee of Shionogi, Inc., Florham Park, NJ, USA. Y.Y. and M.T. are employees of Shionogi & Co., Ltd., Osaka, Japan. R.E. is a consultant for Shionogi and received consultancy fees.

References

    1. Ito, A., Sato T., Ota M., et al. . 2018. In vitro antibacterial properties of cefiderocol, a novel siderophore cephalosporin, against Gram-negative bacteria. Antimicrob. Agents Chemother. 62:e01454-17.
    1. Yamano, Y. 2019. In vitro activity of cefiderocol against a broad range of clinically important Gram-negative bacteria. Clin. Infect. Dis. 69(Suppl 7):S544–S551.
    1. Luscher, A., Moynié L., P.S. Auguste, et al. . 2018. TonB-dependent receptor repertoire of Pseudomonas aeruginosa for uptake of siderophore-drug conjugates. Antimicrob. Agents Chemother. 62:e00097-18.
    1. Page, M.G.P. 2019. The role of iron and siderophores in infection, and the development of siderophore antibiotics. Clin. Infect. Dis. 69(Suppl 7):S529–S537.
    1. Sato, T., and Yamawaki K.. 2019. Cefiderocol: discovery, chemistry, and in vivo profiles of a novel siderophore cephalosporin. Clin. Infect. Dis. 69(Suppl 7):S538–S543.
    1. 2020. Fetroja (cefiderocol) for injection for intravenous use. In Prescribing information. Shionogi, Inc., Florham Park, NJ. Available at Accessed December 20, 2021.
    1. 2020. Fetcroja (cefiderocol 1 g powder for concentrate for solution for infusion). In Shionogi, B.V. Summary of product characteristics. Amsterdam, Netherlands. Available at Accessed December 20, 2021.
    1. Kazmierczak, K.M., Tsuji M., M.G. Wise, et al. . 2019. In vitro activity of cefiderocol, a siderophore cephalosporin, against a recent collection of clinically relevant carbapenem-non-susceptible Gram-negative bacilli, including serine carbapenemase- and metallo-β-lactamase-producing isolates (SIDERO-WT-2014 Study). Int. J. Antimicrob. Agents 53:177–184.
    1. Ito-Horiyama, T., Ishii Y., Ito A., et al. . 2016. Stability of novel siderophore cephalosporin s-649266 against clinically relevant carbapenemases. Antimicrob. Agents Chemother. 60:4384–4386.
    1. Haidar, G., N.J. Philips, R.K. Shields, et al. . 2017. Ceftolozane-tazobactam for the treatment of multidrug-resistant Pseudomonas aeruginosa infections: clinical effectiveness and evolution of resistance. Clin. Infect. Dis. 65:110–120.
    1. Marston, H.D., D.M. Dixon, J.M. Knisely, T.N. Palmore, and Fauci A.S.. 2016. Antimicrobial resistance. JAMA 316:1193–1204.
    1. Shields, R.K., Chen L., Cheng S., et al. . 2017. Emergence of ceftazidime-avibactam resistance due to plasmid-borne blaKPC-3 mutations during treatment of carbapenem-resistant Klebsiella pneumoniae infections. Antimicrob. Agents. Chemother. 61:e02097-16.
    1. Waglechner, N., and Wright G.D.. 2017. Antibiotic resistance: it's bad, but why isn't it worse? BMC Biol. 15:84.
    1. Wunderink, R.G., Matsunaga Y., Ariyasu M., et al. . 2021. Cefiderocol versus high-dose, extended-infusion meropenem for the treatment of Gram-negative nosocomial pneumonia (APEKS-NP): a randomised, double-blind, phase 3, non-inferiority trial. Lancet Infect. Dis. 21:213–225.
    1. Bassetti, M., Echols R., Matsunaga Y., et al. . 2021. Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial. Lancet Infect. Dis. 21:226–240.
    1. Clinical and Laboratory Standards Institute. 2020. Performance standards for antimicrobial susceptibility testing. 30th ed. CLSI supplement M100-S30. CLSI, Wayne, PA.
    1. European Committee on Antimicrobial Susceptibility Testing. 2021. Clinical breakpoints. Available at Accessed April 6, 2021.
    1. Food US and Administration. Drug. 2021. Antibiotic Susceptibility Test Interpretive Criteria. Available at Accessed April 6, 2021.
    1. Katsube, T., Saisho Y.., Shimada J.., and Furuie H.. 2019. Intrapulmonary pharmacokinetics of cefiderocol, a novel siderophore cephalosporin, in healthy adult subjects. J. Antimicrob. Chemother. 74:1971–1974.
    1. Center for Genomic Epidemiology. 2018. ResFinder. Available at Accessed December 20, 2021.
    1. Kohira, N., M.A. Hackel, Ishioka Y., et al. . 2020. Reduced susceptibility mechanism to cefiderocol, a siderophore cephalosporin, among clinical isolates from a global surveillance programme (SIDERO-WT-2014). J. Glob. Antimicrob. Resist. 22:738–741.
    1. Malik, S., Kaminski M., Landman D., et al. . 2020. Cefiderocol resistance in Acinetobacter baumannii: roles of β-lactamases, siderophore receptors and Penicillin Binding Protein 3. Antimicrob. Agents Chemother. 64:e01221-20.
    1. Yamano, Y., Takemura M., and Echols R.. 2020. Potential mechanisms of cefiderocol MIC increase in Enterobacterales in in vitro resistance acquisition studies. Open Forum Infect. Dis. 7(Suppl 1):S730 (abstract).
    1. Kawaguchi, N., Katsube T., Echols R., and Wajima T.. 2021. Population pharmacokinetic and pharmacokinetic/pharmacodynamic analyses of cefiderocol, a parenteral siderophore cephalosporin, in patients with pneumonia, bloodstream infection/sepsis, or complicated urinary tract infection. Antimicrob. Agents Chemother. 65:e01437-20.
    1. Katsube, T., T. Wajima, R. Echols, et al. 2020. Intrapulmonary pharmacokinetics of cefiderocol in hospitalized and ventilated patients receiving standard of care antibiotics for bacterial pneumonia. Open Forum Infect. Dis. 7(Suppl 1):S668 (abstract).
    1. Naseer, S., E.A. Weinstein, D.B. Rubin, et al. . 2021. US Food and Drug Administration (FDA): benefit-risk considerations for cefiderocol (Fetroja®). Clin. Infect. Dis. 72:e1103–e1111.
    1. Kufel, W.D., J.M. Steele, S.W. Riddell, Jones Z., Shakeraneh P., and Endy T.P.. 2020. Cefiderocol for treatment of an empyema due to extensively drug-resistant Pseudomonas aeruginosa: clinical observations and susceptibility testing considerations. IDCases 21:e00863.
    1. Kim, A., Kutschke A., D.E. Ehmann, et al. . 2015. Pharmacodynamic profiling of a siderophore-conjugated monocarbam in Pseudomonas aeruginosa: assessing the risk for resistance and attenuated efficacy. Antimicrob. Agents Chemother. 59:7743–7752.
    1. Tomaras, A.P., J.L. Crandon, C.J. McPherson, et al. . 2013. Adaptation-based resistance to siderophore-conjugated antibacterial agents by Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 57:4197–4207.
    1. Tomaras, A.P., J.L. Crandon, C.J. McPherson, and Nicolau D.P.. 2015. Potentiation of antibacterial activity of the mb-1 siderophore-monobactam conjugate using an efflux pump inhibitor. Antimicrob. Agents Chemother. 59:2439–2442.
    1. Ghazi, I.M., M.L. Monogue, Tsuji M.., and Nicolau D.P.. 2018. Humanized exposures of cefiderocol, a siderophore cephalosporin, display sustained in vivo activity against siderophore-resistant Pseudomonas aeruginosa. Pharmacology 101:278–284.
    1. Choby, J.E., Ozturk T.., S.W. Satola, J.T. Jacob, and Weiss D.S.. 2021. Widespread cefiderocol heteroresistance in carbapenem-resistant Gram-negative pathogens. Lancet Infect. Dis. 21:597–598.
    1. Mack, A.R., M.D. Barnes, M.A. Taracila, et al. . 2020. A standard numbering scheme for class C β-lactamases. Antimicrob. Agents Chemother. 64:e01841-19.

Source: PubMed

Sponsorer og samarbeidspartnere

Medisinsk tilstand

Legemiddelintervensjoner

3
Abonnere